The Recall Desk
Agency classClass IIOur severity:SevereFDA (Drugs)·D-564-2015·Announced 2015-04-29

Attix Pharmaceuticals Recalls Carboxymethyl Dextran Due to Penicillin Cross-Contamination Risk

Attix Pharmaceuticals is recalling Carboxymethyl Dextran active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classification is FDA Class II. Per the rubric, FDA Class II recalls are assigned a score of 4 (Severe), particularly given the risk of severe allergic reactions from penicillin cross-contamination.

Plain-English summary

Attix Pharmaceuticals is recalling all lots of Carboxymethyl Dextran active pharmaceutical ingredient (API) packaged in bags or drums. The product was repackaged and distributed between January 5, 2012, and February 12, 2015.

The recall is being conducted because the product was repackaged in a facility that also handled penicillin products without adequate separation. This process created a potential for cross-contamination with penicillin.

The affected product was distributed nationwide to compounding pharmacies and research organizations. There is no specific instruction for consumers in the source text, but the recall targets professional and research entities.

The recalled product

Product
Carboxymethyl Dextran active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots repackaged and distributed between 01/05/12 to 02/12/15

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 470 recalled by Attix Pharmaceuticals under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 470 products in this recall →

Similar recalls